^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

B-Vaxx

i
Other names: B-Vaxx, B Vaxx, anti-HER2-B-cell-peptide-cancer-vaccine, MVF-HER-2(597-626)/MVF-HER-2 (266-296) Peptide Vaccine
Associations
Company:
Imugene
Drug class:
HER2 inhibitor
Related drugs:
Associations
over1year
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=65, Completed, Robert Wesolowski | Recruiting --> Completed | N=100 --> 65 | Trial completion date: Dec 2023 --> Nov 2022 | Trial primary completion date: Dec 2023 --> Nov 2022
Trial completion • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 expression • EGFR expression
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • B-Vaxx
almost2years
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=100, Recruiting, Pravin Kaumaya | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 expression • EGFR expression
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • B-Vaxx
3years
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=100, Recruiting, Pravin Kaumaya | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
Clinical • Trial completion date • Trial primary completion date • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 expression • EGFR expression
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • B-Vaxx